94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Med.
Sec. Precision Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1513836
This article is part of the Research Topic Women in Science - Precision Medicine 2023 View all 4 articles
Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer
Provisionally accepted- Department of Breast Surgery, Hainan General Hospital, Haikou, China
Breast cancer is the most common malignant tumor in women and the leading cause of cancer-related deaths in women. As one of the most common subtypes of breast cancer, patients with hormone receptor-positive breast cancer usually experience disease progression over an extended period of time, triggering the search for therapeutic strategies other than endocrine therapy. In recent years, continuous research on various targets has led to dramatic changes in the treatment of hormone receptor-positive breast cancer patients, resulting in prolonged clinical survival. With the redefinition of HER2 expression, more precise and individualized treatment is possible. This review comprehensively reviews targeted therapies and critical clinical trials for estrogen receptor-positive breast cancer and tracks the latest advances. It also provides valuable insights into the future direction of targeted therapies.
Keywords: hormone receptor-positive breast cancer, targeted therapy, precision medicine, Female Health, Cancer
Received: 19 Oct 2024; Accepted: 10 Feb 2025.
Copyright: © 2025 Luo, Sun and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yue Sun, Department of Breast Surgery, Hainan General Hospital, Haikou, China
Feng Tie Xu, Department of Breast Surgery, Hainan General Hospital, Haikou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.